JP2025032080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025032080A5 JP2025032080A5 JP2024193416A JP2024193416A JP2025032080A5 JP 2025032080 A5 JP2025032080 A5 JP 2025032080A5 JP 2024193416 A JP2024193416 A JP 2024193416A JP 2024193416 A JP2024193416 A JP 2024193416A JP 2025032080 A5 JP2025032080 A5 JP 2025032080A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- base editor
- regulatory element
- snp
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805271P | 2019-02-13 | 2019-02-13 | |
| US62/805,271 | 2019-02-13 | ||
| US201962850919P | 2019-05-21 | 2019-05-21 | |
| US62/850,919 | 2019-05-21 | ||
| US201962852224P | 2019-05-23 | 2019-05-23 | |
| US201962852228P | 2019-05-23 | 2019-05-23 | |
| US62/852,224 | 2019-05-23 | ||
| US62/852,228 | 2019-05-23 | ||
| US201962873138P | 2019-07-11 | 2019-07-11 | |
| US62/873,138 | 2019-07-11 | ||
| US201962888867P | 2019-08-19 | 2019-08-19 | |
| US62/888,867 | 2019-08-19 | ||
| US201962931722P | 2019-11-06 | 2019-11-06 | |
| US62/931,722 | 2019-11-06 | ||
| US201962941569P | 2019-11-27 | 2019-11-27 | |
| US62/941,569 | 2019-11-27 | ||
| US202062966526P | 2020-01-27 | 2020-01-27 | |
| US62/966,526 | 2020-01-27 | ||
| JP2021546888A JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
| PCT/US2020/018073 WO2020168051A1 (en) | 2019-02-13 | 2020-02-13 | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546888A Division JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025032080A JP2025032080A (ja) | 2025-03-11 |
| JP2025032080A5 true JP2025032080A5 (https=) | 2025-06-16 |
Family
ID=72045106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546888A Active JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
| JP2024193416A Pending JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546888A Active JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230140953A1 (https=) |
| EP (1) | EP3924484A4 (https=) |
| JP (2) | JP7586601B2 (https=) |
| KR (1) | KR20210127206A (https=) |
| CN (2) | CN114040970B (https=) |
| AU (1) | AU2020223306A1 (https=) |
| CA (1) | CA3128876A1 (https=) |
| WO (1) | WO2020168051A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178427A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CA3128755C (en) | 2019-02-13 | 2024-06-04 | Beam Therapeutics Inc. | Compositions and methods for treating hemoglobinopathies |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP3956449B1 (en) | 2019-04-15 | 2026-02-25 | EdiGene Therapeutics (Beijing) Inc. | Methods and compositions for editing rnas |
| EP3997229A4 (en) | 2019-07-12 | 2024-07-03 | Peking University | TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| KR20220119129A (ko) * | 2019-12-30 | 2022-08-26 | 에디진 테라퓨틱스 (베이징) 인크. | Leaper 기술에 기반한 mps ih 치료 방법 및 조성물 |
| WO2021163587A1 (en) * | 2020-02-13 | 2021-08-19 | Beam Therapeutics Inc. | Compositions and methods for engraftment of base edited cells |
| US20230340486A1 (en) * | 2020-07-27 | 2023-10-26 | The Children’S Hospital Of Philadelphia | In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US20240110177A1 (en) * | 2020-10-21 | 2024-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | A screening platform for adar-recruiting guide rnas |
| KR20240007651A (ko) * | 2021-04-16 | 2024-01-16 | 빔 테라퓨틱스, 인크. | 간세포의 유전적 변형 |
| AU2022272250A1 (en) * | 2021-05-14 | 2023-11-30 | Beam Therapeutics Inc. | Compositions and methods for treating transthyretin amyloidosis |
| WO2022246266A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| EP4426821A1 (en) * | 2021-11-02 | 2024-09-11 | University of Massachusetts | Nme2cas9 inlaid domain fusion proteins |
| EP4441219A2 (en) * | 2021-12-01 | 2024-10-09 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides for rna editing targeting lrrk2 |
| WO2023169454A1 (zh) * | 2022-03-08 | 2023-09-14 | 中国科学院遗传与发育生物学研究所 | 腺嘌呤脱氨酶及其在碱基编辑中的用途 |
| CN114686456B (zh) * | 2022-05-10 | 2023-02-17 | 中山大学 | 基于双分子脱氨酶互补的碱基编辑系统及其应用 |
| JP2025530183A (ja) * | 2022-09-08 | 2025-09-11 | ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ | レット症候群治療法 |
| WO2024230760A1 (zh) * | 2023-05-09 | 2024-11-14 | 北京齐禾生科生物科技有限公司 | 一种可作用于dna的腺苷脱氨酶及其应用 |
| WO2024233941A1 (en) * | 2023-05-11 | 2024-11-14 | Massachusetts Eye And Ear Infirmary | Base editing approaches to treat abca4-associated stargardt disease |
| WO2024238623A1 (en) * | 2023-05-15 | 2024-11-21 | University Of Georgia Research Foundation, Inc. | Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2 |
| CN117965505A (zh) * | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
| CN120536418A (zh) * | 2024-02-26 | 2025-08-26 | 尧唐(上海)生物科技有限公司 | 一种脱氨酶变体、包含其的碱基编辑器及其应用 |
| WO2025184515A1 (en) * | 2024-02-29 | 2025-09-04 | Vesigen, Inc. | Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004778A1 (en) * | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| BR112017007765B1 (pt) * | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| CN110214183A (zh) * | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| KR102622411B1 (ko) * | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US11866697B2 (en) * | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| KR102761791B1 (ko) * | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| CN109306361B (zh) * | 2018-02-11 | 2022-06-28 | 华东师范大学 | 一种新的a/t到g/c碱基定点转换的基因编辑系统 |
| CN109295186B (zh) * | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
-
2020
- 2020-02-13 US US17/430,672 patent/US20230140953A1/en active Pending
- 2020-02-13 EP EP20756724.9A patent/EP3924484A4/en active Pending
- 2020-02-13 JP JP2021546888A patent/JP7586601B2/ja active Active
- 2020-02-13 CA CA3128876A patent/CA3128876A1/en active Pending
- 2020-02-13 WO PCT/US2020/018073 patent/WO2020168051A1/en not_active Ceased
- 2020-02-13 CN CN202080028186.5A patent/CN114040970B/zh active Active
- 2020-02-13 KR KR1020217029268A patent/KR20210127206A/ko active Pending
- 2020-02-13 CN CN202411269394.0A patent/CN119280261A/zh active Pending
- 2020-02-13 AU AU2020223306A patent/AU2020223306A1/en active Pending
-
2024
- 2024-11-05 JP JP2024193416A patent/JP2025032080A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032080A5 (https=) | ||
| JP2022520080A5 (https=) | ||
| Pfaller et al. | Adenosine deaminases acting on RNA (ADARs) and viral infections | |
| Dimmock et al. | Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals? | |
| Albertini et al. | Crystal structure of the rabies virus nucleoprotein-RNA complex | |
| DE69429260T3 (de) | Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie | |
| US20180236103A1 (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| Lipskaya et al. | Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine‐associated polio cases | |
| Rodriguez-Frias et al. | Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach | |
| JP2021519791A5 (https=) | ||
| EP2966170A1 (en) | HBV inactivation | |
| JP2008533988A5 (https=) | ||
| JP2022545950A5 (https=) | ||
| BR112020015821A2 (pt) | Composições e métodos para induzir sinalização de proteína 16 contendo motivo tripartido | |
| Rozhon et al. | Analysis of genetic variation in Theiler's virus during persistent infection in the mouse central nervous system | |
| Buckler-White et al. | Characterization of a gene coding for M proteins which is involved in host range restriction of an avian influenza A virus in monkeys | |
| Florian et al. | Characterization of the anti‐HBV activity of HLP1–23, a human lactoferrin‐derived peptide | |
| Wittkop et al. | Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation | |
| Ljungquist et al. | DNA sequences of the repressor gene and operator region of bacteriophage P2. | |
| Bink et al. | Protonation of non-Watson–Crick base pairs and encapsidation of turnip yellow mosaic virus RNA | |
| EP0719328A1 (fr) | Gene grb3-3, ses variants et leurs utilisations | |
| EP4333875A1 (en) | Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders | |
| JP2020506714A5 (https=) | ||
| WO2018030534A1 (ja) | Ｂ型肝炎治療用組成物、及びｂ型肝炎ウイルスの複製活性の評価方法 | |
| He et al. | An engineered mutant of a host phospholipid synthesis gene inhibits viral replication without compromising host fitness |